ALK-Abelló A/S (CPH: ALK.B)

Market Cap	39.59B
Revenue (ttm)	5.18B
Net Income (ttm)	690.00M
Shares Out	221.19M
EPS (ttm)	3.21
PE Ratio	55.75
Forward PE	39.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,923
Open	178.10
Previous Close	178.00
Day's Range	175.30 - 178.60
52-Week Range	74.30 - 185.60
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About ALK-Abelló

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1923
• Employees: 2,824
• Stock Exchange: Nasdaq Copenhagen
• Ticker Symbol: ALK.B

Financial Performance

In 2023, ALK-Abelló's revenue was 4.82 billion, an increase of 6.94% compared to the previous year's 4.51 billion. Earnings were 486.00 million, an increase of 45.07%.